Psoriasis Clinical Trials

Showing 641-660 of 888 trials

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

NCT00287118

An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.

Candidates for Systemic Therapy for PsoriasisPsoriasis

Merck KGaA, Darmstadt, Germany189 participantsStarted Oct 2004

Geneva, Switzerland

COMPLETEDPhase 1

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013

The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.

Psoriasis

Novan, Inc.36 participantsStarted Oct 2017

Boise, Idaho, United States • Austin, Texas, United States • College Station, Texas, United States +1 more locations

COMPLETEDPhase 3

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

NCT02196701

The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.

Psoriasis

AbbVie46 participantsStarted Aug 2014

UNKNOWNPhase 1

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

NCT02918123

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Psoriasis

Kang Stem Biotech Co., Ltd.9 participantsStarted Jan 2018

Seoul, South Korea

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Related Searches

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

Identification of New Prognostic Markers in Psoriatic Arthritis

Can We Miss Pigmented Lesions in Psoriasis Patients?

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis